Adenovirus vector-based vaccine for infectious diseases

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Chan, J. F., Kok, K., Zhu, Z., Chu, H., To, K. K., Yuan, S., & Yuen, K. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1719902 · Cited by 3,127

Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5

Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt‐Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., & Finberg, R. W. (1997) · Science · doi:10.1126/science.275.5304.1320 · Cited by 3,102

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259

Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment

Wickham, T. J., Mathias, P., Cheresh, D. A., & Nemerow, G. R. (1993) · Cell · doi:10.1016/0092-8674(93)90231-e · Cited by 2,199

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00234-8 · Cited by 1,747

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713

CGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING.

Ablasser, A., Goldeck, M., Cavlar, T., Deimling, T., Witte, G., Röhl, I., Hopfner, K.-P., Ludwig, J., & Hornung, V. (2013) · Nature · doi:10.1038/nature12306 · Cited by 1,695

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31605-6 · Cited by 1,225

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., Grousova, D. M., Erokhova, A. S., Kovyrshina, A. V., Botikov, A. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31866-3 · Cited by 1,055

The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response

Muruve, D. A., Pétrilli, V., Zaiss, A. K., White, L. R., Clark, S. A., Ross, P. J., Parks, R. J., & Tschopp, J. (2008) · Nature · doi:10.1038/nature06664 · Cited by 965

CD46 is a cellular receptor for group B adenoviruses

Gaggar, A., Shayakhmetov, D. M., & Lieber, A. (2003) · Nature Medicine · doi:10.1038/nm952 · Cited by 793

Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques

Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis

McElrath, M. J., Rosa, S. C. D., Moodie, Z., Dubey, S. A., Kierstead, L. S., Janes, H., Defawe, O., Carter, D. K., Hural, J., Akondy, R. S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61592-5 · Cited by 712

The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction

Cohen, C. J., Shieh, J. T. C., Pickles, R. J., Okegawa, T., Hsieh, J., & Bergelson, J. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261452898 · Cited by 702

Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer

Waddington, S. N., McVey, J. H., Bhella, D., Parker, A. L., Barker, K., Atoda, H., Pink, R., Buckley, S. M. K., Greig, J. A., Denby, L., et al. (2008) · Cell · doi:10.1016/j.cell.2008.01.016 · Cited by 644

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Emary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00628-0 · Cited by 603

Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21)

Mallery, D. L., McEwan, W. A., Bidgood, S. R., Towers, G. J., Johnson, C. M., & James, L. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014074107 · Cited by 517

Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D

Abbink, P., Lemckert, A. A. C., Ewald, B. A., Lynch, D. M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A. R., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02696-06 · Cited by 503

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

Roberts, D. M., Nanda, A., Havenga, M. J. E., Abbink, P., Lynch, D. M., Ewald, B. A., Liu, J., Thorner, A. R., Swanson, P. E., Gorgone, D. A., et al. (2006) · Nature · doi:10.1038/nature04721 · Cited by 490

Anticipating the international spread of Zika virus from Brazil

Bogoch, I. I., Brady, O. J., Kraemer, M. U. G., German, M. L., Creatore, M., Kulkarni, M. A., Brownstein, J. S., Mekaru, S. R., Hay, S. I., Groot, E., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00080-5 · Cited by 464

Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors

Onomoto, K., Onoguchi, K., & Yoneyama, M. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00602-7 · Cited by 440

Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14

Wang, H., Li, Z.-Y., Liu, Y., Persson, J., Beyer, I., Möller, T., Koyuncu, D., Drescher, M. R., Strauss, R., Zhang, X., et al. (2010) · Nature Medicine · doi:10.1038/nm.2270 · Cited by 436

PEGylation of Adenovirus with Retention of Infectivity and Protection from Neutralizing Antibody in Vitro and in Vivo

O’Riordan, C. R., Lachapelle, A., Delgado, C., Parkes, V., Wadsworth, S. C., Smith, A. E., & Francis, G. E. (1999) · Human Gene Therapy · doi:10.1089/10430349950018021 · Cited by 409

Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism

Krasnykh, V. N., Mikheeva, G., Douglas, J. T., & Curiel, D. T. (1996) · Journal of Virology · doi:10.1128/jvi.70.10.6839-6846.1996 · Cited by 387

A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity

Dicks, M. D. J., Spencer, A. J., Edwards, N. J., Wadell, G., Bojang, K., Gilbert, S. C., Hill, A. V. S., & Cottingham, M. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040385 · Cited by 384

Basolateral Localization of Fiber Receptors Limits Adenovirus Infection from the Apical Surface of Airway Epithelia

Walters, R. W., Grunst, T., Bergelson, J. M., Finberg, R. W., Welsh, M. J., & Zabner, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.15.10219 · Cited by 372

ISOLATION AND PARTIAL CHARACTERISATION OF A NEW VIRUS CAUSING ACUTE HÆMORRHAGIC FEVER IN ZAIRE

Johnson, K. M., Lange, J., Webb, P. A., & Murphy, F. A. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92000-1 · Cited by 371

Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein

Sumida, S. M., Truitt, D. M., Lemckert, A. A. C., Vogels, R., Custers, J. H. H. V., Addo, M. M., Lockman, S., PETER, T. F., Peyerl, F. W., Kishko, M., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.7179 · Cited by 369

Efficient Gene Transfer into Human CD34 + Cells by a Retargeted Adenovirus Vector

Shayakhmetov, D. M., Papayannopoulou, T., Stamatoyannopoulos, G., & Lieber, A. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2567-2583.2000 · Cited by 367

Adenovirus Type 11 Uses CD46 as a Cellular Receptor

Segerman, A., Atkinson, J. P., Marttila, M., Dennerquist, V., Wadell, G., & Arnberg, N. (2003) · Journal of Virology · doi:10.1128/jvi.77.17.9183-9191.2003 · Cited by 356

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

Stanley, D. A., Honko, A. N., Asiedu, C. K., Trefry, J. C., Lau-Kilby, A. W., Johnson, J. C., Hensley, L. E., Ammendola, V., Abbate, A., Grazioli, F., et al. (2014) · Nature Medicine · doi:10.1038/nm.3702 · Cited by 350

Adenovirus Type 37 Uses Sialic Acid as a Cellular Receptor

Arnberg, N., Edlund, K., Kidd, A. H., & Wadell, G. (2000) · Journal of Virology · doi:10.1128/jvi.74.1.42-48.2000 · Cited by 316

The role of the nuclear pore complex in adenovirus DNA entry

Greber, U. F., Suomalainen, M., Stidwill, R. P., Boucke, K., Ebersold, M. W., & Helenius, A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.19.5998 · Cited by 299

Replication-Defective Vector Based on a Chimpanzee Adenovirus

Farina, S. F., Gao, G., Xiang, Z. Q., Rux, J. J., Burnett, R. M., Alvira, M. R., Marsh, J. A., Ertl, H. C. J., & Wilson, J. M. (2001) · Journal of Virology · doi:10.1128/jvi.75.23.11603-11613.2001 · Cited by 269

Prevalence of Neutralizing Antibodies to Adenoviral Serotypes 5 and 35 in the Adult Populations of The Gambia, South Africa, and the United States

Nwanegbo, E. C., Vardas, E., Gao, W., Whittle, H. C., Sun, H., Rowe, D., Robbins, P. D., & Gambotto, A. A. (2004) · Clinical and Vaccine Immunology · doi:10.1128/cdli.11.2.351-357.2004 · Cited by 266

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques

van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J. N., Port, J. R., Avanzato, V., Bushmaker, T., Flaxman, A., Ulaszewska, M., et al. (2020) · doi:10.1101/2020.05.13.093195 · Cited by 246

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans

Kampen, K. R. V., Shi, Z., Gao, P., Zhang, J., Foster, K. W., Chen, D., Marks, D. H., Elmets, C. A., & Tang, D.-C. C. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.07.043 · Cited by 220

Adenovirus Vector-Induced Innate Inflammatory Mediators, MAPK Signaling, As Well As Adaptive Immune Responses Are Dependent upon Both TLR2 and TLR9 In Vivo

Appledorn, D. M., Patial, S., McBride, A. J., Godbehere, S., van Rooijen, N., Parameswaran, N., & Amalfitano, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.2134 · Cited by 201

Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial

Zhu, F., Hou, L., Li, J., Wu, S., Liu, P., Zhang, G., Hu, Y., Meng, F., Xu, J., Tang, R., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60553-0 · Cited by 191

Mapping and role of T cell response in SARS-CoV-2–infected mice

Zhuang, Z., Lai, X., Sun, J., Chen, Z., Zhang, Z., Dai, J., Liu, D., Li, Y., Li, F., Wang, Y., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202187 · Cited by 175

Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine

Gray, G., Buchbinder, S., & Duerr, A. C. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32833d2d2b · Cited by 172

Expression of the Primary Coxsackie and Adenovirus Receptor Is Downregulated during Skeletal Muscle Maturation and Limits the Efficacy of Adenovirus-Mediated Gene Delivery to Muscle Cells

Nalbantoglu, J. N., Pari, G., Karpati, G., & Holland, P. C. (1999) · Human Gene Therapy · doi:10.1089/10430349950018409 · Cited by 169

A Single Intranasal or Intramuscular Immunization with Chimpanzee Adenovirus Vectored SARS-CoV-2 Vaccine Protects Against Pneumonia in Hamsters

Bricker, T. L., Darling, T. L., Hassan, A. O., Harastani, H., Soung, A., Jiang, X., Dai, Y.-N., Zhao, H., Adams, L. J., Holtzman, M. J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109400 · Cited by 168

Novel Replication-Incompetent Vector Derived from Adenovirus Type 11 (Ad11) for Vaccination and Gene Therapy: Low Seroprevalence and Non-Cross-Reactivity with Ad5

Holterman, L., Vogels, R., van der Vlugt, R., Sieuwerts, M., Grimbergen, J. M., Kaspers, J., Geelen, E., van der Helm, E., Lemckert, A. A. C., Gillissen, G. F., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.23.13207-13215.2004 · Cited by 148

Adenovirus-Based Vaccines: Comparison of Vectors from Three Species of Adenoviridae

Chen, H., Xiang, Z., Li, Y., Kurupati, R. K., Jia, B., Bian, A., Zhou, D., Hutnick, N. A., Yuan, S., Gray, C., et al. (2010) · Journal of Virology · doi:10.1128/jvi.00450-10 · Cited by 145

Toll-like Receptor 9 Triggers an Innate Immune Response to Helper-dependent Adenoviral Vectors

Cerullo, V., Seiler, M. P., Mane, V. P., Brunetti‐Pierri, N., Clarke, C., Bertin, T., Rodgers, J. R., & Lee, B. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300031 · Cited by 143

Adenovirus Vaccines in the U.S. Military

Gaydos, C. A., & Gaydos, J. C. (1995) · Military Medicine · doi:10.1093/milmed/160.6.300 · Cited by 139

Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults

Coughlan, L., Sridhar, S., Payne, R., Edmans, M. D., Milicic, A., Venkatraman, N., Lugonja, B., Clifton, L., Qi, C., Folegatti, P. M., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.02.011 · Cited by 138

MAIT cell activation augments adenovirus vector vaccine immunogenicity

Provine, N. M., Amini, A., Garner, L. C., Spencer, A. J., Dold, C., Hutchings, C. L., Silva-Reyes, L., FitzPatrick, M. E. B., Chinnakannan, S. K., Oguti, B., et al. (2021) · Science · doi:10.1126/science.aax8819 · Cited by 132

Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling

Quinn, K. M., Zak, D. E., Costa, A. D. S., Yamamoto, A., Kastenmüller, K., Hill, B. J., Lynn, G. M., Darrah, P. A., Lindsay, R. W. B., Wang, L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78280 · Cited by 113

Bilamellar Cationic Liposomes Protect Adenovectors from Preexisting Humoral Immune Responses

Yotnda, P., Chen, D.-H., Chiu, W., Piedra, P. A., Davis, A. R., Templeton, N. S., & Brenner, M. K. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0545 · Cited by 111

Circumvention of Immunity to the Adenovirus Major Coat Protein Hexon

Roy, S., Shirley, P. S., McClelland, A., & Kaleko, M. (1998) · Journal of Virology · doi:10.1128/jvi.72.8.6875-6879.1998 · Cited by 111

Identification and quantification of complement regulator CD46 on normal human tissues.

Johnstone, R. W., Loveland, B. E., & McKenzie, I. F. C. (1993) · PubMed · Cited by 108

Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9‐dependent maturation and IFN‐α production

Basner‐Tschakarjan, E., Gaffal, E., O’Keeffe, M. A., Tormo, D., Limmer, A., Wagner, H., Hochrein, H., & Tüting, T. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.964 · Cited by 102

Development and Assessment of Human Adenovirus Type 11 as a Gene Transfer Vector

Stone, D., Ni, S., Li, Z.-Y., Gaggar, A., Paolo, N. C. D., Feng, Q., Sandig, V., & Lieber, A. (2005) · Journal of Virology · doi:10.1128/jvi.79.8.5090-5104.2005 · Cited by 102

Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy

Li, R., Xiaohua, T., Li, Y., Zhang, H., Ma, R., Ji, T., Dong, W., Tong, T., Liu, Y., Chen, D., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.02.025 · Cited by 101

Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector

Sakurai, F., Mizuguchi, H., Yamaguchi, T., & Hayakawa, T. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00243-0 · Cited by 100

Human adenovirus type 26 uses sialic acid–bearing glycans as a primary cell entry receptor

Baker, A. T., Mundy, R. M., Davies, J. A., Rizkallah, P. J., & Parker, A. L. (2019) · Science Advances · doi:10.1126/sciadv.aax3567 · Cited by 92

Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector

Sakurai, F., Mizuguchi, H., & Hayakawa, T. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301959 · Cited by 88

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

Baden, L. R., Stieh, D. J., Sarnecki, M., Walsh, S. R., Tomaras, G. D., Kublin, J. G., McElrath, M. J., Alter, G., Ferrari, G., Montefiori, D. C., et al. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30229-0 · Cited by 88

Role of MyD88 and TLR9 in the Innate Immune Response Elicited by Serotype 5 Adenoviral Vectors

Yamaguchi, T., Kawabata, K., Koizumi, N., Sakurai, F., Kaneda‐Nakashima, K., Sakurai, H., Sasaki, T., Okada, N., Yamanishi, K., & Mizuguchi, H. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.016 · Cited by 87

Adenovirus Virus-Associated RNAs Induce Type I Interferon Expression through a RIG-I-Mediated Pathway

Minamitani, T., Iwakiri, D., & Takada, K. (2011) · Journal of Virology · doi:10.1128/jvi.02160-10 · Cited by 87

Innate immunity to adenovirus: lessons from mice

Atasheva, S., Yao, J., & Shayakhmetov, D. M. (2019) · FEBS Letters · doi:10.1002/1873-3468.13696 · Cited by 87

A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity

Matsuda, K., Migueles, S. A., Huang, J., Bolkhovitinov, L., Stuccio, S., Griesman, T., Pullano, A. A., Kang, B. H., Ishida, E., Zimmerman, M. G., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140794 · Cited by 86

Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity

Lemckert, A. A. C., Grimbergen, J. M., Smits, S., Hartkoorn, E., Holterman, L., Berkhout, B., Barouch, D. H., Vogels, R., Quax, P. H. A., Goudsmit, J., et al. (2006) · Journal of General Virology · doi:10.1099/vir.0.82079-0 · Cited by 85

A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti–Zika Virus Vaccine

Salisch, N. C., Stephenson, K. E., Williams, K. L., Cox, F., van der Fits, L., Heerwegh, D., Truyers, C., Habets, M. N., Kanjilal, D. G., Larocca, R. A., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m20-5306 · Cited by 81

A Recombinant E1-Deleted Canine Adenoviral Vector Capable of Transduction and Expression of a Transgene in Human-Derived Cells and In Vivo

Klonjkowski, B., Gilardi‐Hebenstreit, P., Hadchouel, J., Randrianarison-Huetz, V., Boutin, S., Yeh, P., Perricaudet, M., & Kremer, E. J. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.17-2103 · Cited by 80

Human mastadenovirus type 70: a novel, multiple recombinant species D mastadenovirus isolated from diarrhoeal faeces of a haematopoietic stem cell transplantation recipient

Hage, E., Liebert, U. G., Bergs, S., Ganzenmueller, T., & Heim, A. (2015) · Journal of General Virology · doi:10.1099/vir.0.000196 · Cited by 80

Multiple Innate Immune Pathways Contribute to the Immunogenicity of Recombinant Adenovirus Vaccine Vectors

Rhee, E. G., Blattman, J. N., Kasturi, S. P., Kelley, R., Kaufman, D. R., Lynch, D. M., Porte, A. L., Simmons, N. L., Clark, S., Pulendran, B., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01597-10 · Cited by 79

Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization

Cheng, C., Gall, J. G. D., Nason, M., King, C. R., Koup, R. A., Roederer, M., McElrath, M. J., Morgan, C. A., Churchyard, G., Baden, L. R., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00866-09 · Cited by 78

Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage

Xu, K., Song, Y., Dai, L., Zhang, Y., Lu, X., Xie, Y., Zhang, H., Tao, C., Wang, Q., Huang, Q., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01722-17 · Cited by 77

Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial

Hayton, E., Rose, A., Ibrahimsa, U., Sorbo, M. D., Capone, S., Crook, A., Black, A. P., Dorrell, L., & Hanke, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101591 · Cited by 74

Immunogenicity and Protection of a Recombinant Human Adenovirus Serotype 35-Based Malaria Vaccine againstPlasmodium yoeliiin Mice

Ophorst, O. J. A. E., Radošević, K., Havenga, M. J. E., Pau, M. G., Holterman, L., Berkhout, B., Goudsmit, J., & Tsuji, M. (2005) · Infection and Immunity · doi:10.1128/iai.74.1.313-320.2006 · Cited by 73

Trafficking of Antigen-Specific CD8+ T-Lymphocytes to Mucosal Surfaces Following Intramuscular Vaccination

Kaufman, D., Liu, J.-Y., Carville, A., Mansfield, K., Havenga, M., Goudsmit, J., & Barouch, D. (2008) · Journal of Immunology · doi:10.4049/jimmunol.181.6.4188 · Cited by 72

Induction of type I interferon by adenovirus-encoded small RNAs

Yamaguchi, T., Kawabata, K., Kouyama, E., Ishii, K. J., Katayama, K., Suzuki, T., Kurachi, S., Sakurai, F., Akira, S., & Mizuguchi, H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009823107 · Cited by 66

Route of Adenovirus-Based HIV-1 Vaccine Delivery Impacts the Phenotype and Trafficking of Vaccine-Elicited CD8 + T Lymphocytes

Kaufman, D. R., Bivas‐Benita, M., Simmons, N. L., Miller, D. D., & Barouch, D. H. (2010) · Journal of Virology · doi:10.1128/jvi.02563-09 · Cited by 66

Induction of HIV-1–Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 HIV-1 Vaccination of Humans

Baden, L. R., Liu, J., Li, H., Johnson, J. A., Walsh, S. R., Kleinjan, J. A., Engelson, B. A., Peter, L. E., Abbink, P., Milner, D. A., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu485 · Cited by 66

The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform

Volkmann, A., Williamson, A., Weidenthaler, H., Meyer, T. P. H., Robertson, J. S., Excler, J., CONDIT, R. C., Evans, E., Smith, E. R., Kim, D., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.08.050 · Cited by 61

Diminished Innate Antiviral Response to Adenovirus Vectors in cGAS/STING-Deficient Mice Minimally Impacts Adaptive Immunity

Anghelina, D., Lam, E., & Falck-Pedersen, E. (2016) · Journal of Virology · doi:10.1128/jvi.00500-16 · Cited by 59

Ebola from emergence to epidemic: the virus and the disease, global preparedness and perspectives

Dhama, K., Malik, Y. S., Malik, S. V. S., & Singh, R. K. (2015) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.6197 · Cited by 57

Immunization With a Novel Human Type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models

Guo, Q., Chan, J. F., Poon, V. K., Wu, S., Chan, C. C., Hou, L., Yip, C. C., Ren, C., Cai, J., Zhao, M., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy187 · Cited by 57

Membrane Cofactor Protein (CD46) Is a Basolateral Protein That Is Not Endocytosed

Maisner, A., Zimmer, G., Liszewski, M. K., Lublin, D. M., Atkinson, J. P., & Herrler, G. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.33.20793 · Cited by 46

Replicating Adenovirus-Simian Immunodeficiency Virus (SIV) Vectors Efficiently Prime SIV-Specific Systemic and Mucosal Immune Responses by Targeting Myeloid Dendritic Cells and Persisting in Rectal Macrophages, Regardless of Immunization Route

Patterson, L. J., Kuate, S., Daltabuit-Test, M., Li, Q., Xiao, P., McKinnon, K. M., DiPasquale, J., Cristillo, A. D., Venzon, D. J., Haase, A. T., et al. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00010-12 · Cited by 46

Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines

Hwang, J., Lee, S. B., Lee, S. W., Lee, M. H., Koyanagi, A., Jacob, L., Tizaoui, K., Yon, D. K., Shin, J. I., & Smith, L. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102681 · Cited by 45

Anionic Liposomes Increase the Efficiency of Adenovirus-Mediated Gene Transfer to Coxsackie-Adenovirus Receptor Deficient Cells

Zhong, Z., Shi, S., Han, J., Zhang, Z., & Sun, X. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900151k · Cited by 44

Priming and Activation of Inflammasome by Canarypox Virus Vector ALVAC via the cGAS/IFI16–STING–Type I IFN Pathway and AIM2 Sensor

Liu, F., Niu, Q., Fan, X., Liu, C., Zhang, J., Wei, Z., Hou, W., Kanneganti, T., Robb, M. L., Kim, J. H., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700698 · Cited by 44

Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles

Kakiuchi, Y., Kuroda, S., Kanaya, N., Kumon, K., Tsumura, T., Hashimoto, M., Yagi, C., Sugimoto, R., Hamada, Y., Kikuchi, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.015 · Cited by 44

Creation of a panel of vectors based on ape adenovirus isolates

Roy, S., Medina‐Jaszek, A., Wilson, M. J., Sandhu, A. K., Calcedo, R., Lin, J., & Wilson, J. M. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1530 · Cited by 43

A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2

Sørensen, A. L. T., Rolland, M., Hartmann, J. P., Harboe, Z. B., Roed, C., Jensen, T. Ø., Kolte, L., Fassi, D. E., Hillingsø, J., Radziwon‐Balicka, A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004904 · Cited by 41

Extracellular Vesicles-Mimetic Encapsulation Improves Oncolytic Viro-Immunotherapy in Tumors With Low Coxsackie and Adenovirus Receptor

Zhang, Y., Wu, J., Zhang, H., Wei, J., & Wu, J. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.574007 · Cited by 40

Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge

Park, K. S., Lee, J., Ahn, S. S., Byun, Y.-H., Seong, B. L., Baek, Y. H., Song, M., Choi, Y. K., Na, Y. J., Hwang, I., et al. (2009) · Virology · doi:10.1016/j.virol.2009.09.018 · Cited by 39

Protective Efficacy of a Single Immunization of a Chimeric Adenovirus Vector-Based Vaccine against Simian Immunodeficiency Virus Challenge in Rhesus Monkeys

Barouch, D. H., Liu, J., Lynch, D. M., O’Brien, K. L., Porte, A. L., Simmons, N. L., Riggs, A. M., Clark, S., Abbink, P., Montefiori, D. C., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00821-09 · Cited by 36

TRIF, and TRIF-Interacting TLRs Differentially Modulate Several Adenovirus Vector-Induced Immune Responses

Appledorn, D., Patial, S., Godbehere, S., Parameswaran, N., & Amalfitano, A. (2009) · Journal of Innate Immunity · doi:10.1159/000207194 · Cited by 33

Lactoferrin Retargets Human Adenoviruses to TLR4 to Induce an Abortive NLRP3-Associated Pyroptotic Response in Human Phagocytes

Chéneau, C., Eichholz, K., Tran, T. H., Tran, T. T. P., Paris, O., Henriquet, C., Bajramovic, J. J., Pugnière, M., & Kremer, E. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.685218 · Cited by 31

Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors

Verhaagh, S., de Jong, E., Goudsmit, J., Lecollinet, S., Gillissen, G. F., de Vries, M. R., van Leuven, K., Que, I., Ouwehand, K., Mintardjo, R., et al. (2006) · Journal of General Virology · doi:10.1099/vir.0.81293-0 · Cited by 30

A rapid strategy for constructing novel simian adenovirus vectors with high viral titer and expressing highly antigenic proteins applicable for vaccine development

Luo, S., Zhang, P., Ma, X., Wang, Q., Lu, J., Liu, B., Zhao, W., Allain, J., Li, C.-Y., & Li, T. (2019) · Virus Research · doi:10.1016/j.virusres.2019.05.008 · Cited by 23

Improvement of transduction efficiency of recombinant adenovirus vector conjugated with cationic liposome for human oral squamous cell carcinoma cell lines

Fukuhara, H., Hayashi, Y., Yamamoto, N., Fukui, T., Nishikawa, M., Mitsudo, K., Tohnai, I., Ueda, M., Mizuno, M., & Yoshida, J. (2003) · Oral Oncology · doi:10.1016/s1368-8375(03)00047-2 · Cited by 21

Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction

Suzuki‐Kouyama, E., Katayama, K., Sakurai, F., Yamaguchi, T., Kurachi, S., Kawabata, K., Nakagawa, S., & Mizuguchi, H. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.10.060 · Cited by 18

Humoral Responses Elicited by Adenovirus Displaying Epitopes Are Induced Independently of the Infection Process and Shaped by the Toll-Like Receptor/MyD88 Pathway

Anchim, A., Raddi, N., Zig, L., Perrieau, P., Goffic, R. L., Ryffel, B., & Benihoud, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00124 · Cited by 16

T Helper 17 Promotes Induction of Antigen-Specific Gut-Mucosal Cytotoxic T Lymphocytes following Adenovirus Vector Vaccination

Hemmi, M., Tachibana, M., Fujimoto, N., Shoji, M., Sakurai, F., Kobiyama, K., Ishii, K. J., Akira, S., & Mizuguchi, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01456 · Cited by 11

A hexon-specific PEGylated adenovirus vector utilizing blood coagulation factor X

Matsui, H., Sakurai, F., Katayama, K., Yamaguchi, T., Okamoto, S., Takahira, K., Tachibana, M., Nakagawa, S., & Mizuguchi, H. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.02.011 · Cited by 10

Type-I IFN signaling is required for the induction of antigen-specific CD8+ T cell responses by adenovirus vector vaccine in the gut-mucosa

Shoji, M., Tachibana, M., Katayama, K., Tomita, K., Tsuzuki, S., Sakurai, F., Kawabata, K., Ishii, K. J., Akira, S., & Mizuguchi, H. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.056 · Cited by 8

Downregulation of CD46 During Muscle Differentiation: Implications for Gene Transfer to Human Skeletal Muscle Using Group B Adenoviruses

Larochelle, N., Deol, J. R., Srivastava, V. K., Allen, C. A., Mizuguchi, H., Karpati, G., Holland, P. C., & Nalbantoglu, J. N. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.040 · Cited by 7

Influenza vaccine for 2020-2021.

(2020) · PubMed · Cited by 3

COVID-19 mRNA vaccines: Platforms and current developments

Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases

Wang, S., Liang, B., Wang, W., Li, L., Feng, N., Zhao, Y., Wang, T., Yan, F., Yang, S., & Xia, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01408-5 · Cited by 230

Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives

Souto, E. B., Blanco-Llamero, C., Krambeck, K., Kiran, N. S., Yashaswini, C., Postwala, H. I., Severino, P. B., Priefer, R., Prajapati, B. G., & Maheshwari, R. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.04.010 · Cited by 184

Two centuries of vaccination: historical and conceptual approach and future perspectives

Montero, D. A., Vidal, R. M., Velasco, J., Carreño, L. J., Torres, J. P., O., M. A. B., Tovar-Rosero, Y.-Y., Oñate, A. A., & O’Ryan, M. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1326154 · Cited by 171

Chitosan-Based Nanomaterial as Immune Adjuvant and Delivery Carrier for Vaccines

Gong, X., Gao, Y., Shu, J., Zhang, C., & Zhao, K. (2022) · Vaccines · doi:10.3390/vaccines10111906 · Cited by 140

Modeling comorbidity of depression and anxiety in rats

Chkhetiani, M. (2008) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2008.05.187

Adenoviral Vector Immunity: Its Implications and Circumvention Strategies

S. Ahi, Y., S. Bangari, D., & K. Mittal, S. (2011) · Current Gene Therapy · doi:10.2174/156652311796150372 · Cited by 185

Adenovirus Vectors: Excellent Tools for Vaccine Development

Chang, J. (2021) · Immune Network · doi:10.4110/in.2021.21.e6 · Cited by 129

Engineered adenovirus serotypes for overcoming anti-vector immunity

Dharmapuri, S., Peruzzi, D., & Aurisicchio, L. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903187053 · Cited by 38

Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.

Hartman, Z. C., Appledorn, D. M., & Amalfitano, A. (2008) · Virus Research · doi:10.1016/j.virusres.2007.10.005 · Cited by 239